Amgen Smashes Q2 Earnings Expectations with Strong Growth

Amgen (NASDAQ:AMGN), a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses, reported strong Q2 CY2026 numbers. The company beat Wall Street's revenue expectations with sales up 9.5% year on year to $10.05 billion.

The full-year revenue guidance of $38.8 billion at the midpoint came in 2.8% above analysts' estimates, while non-GAAP profit of $6.29 per share was 12% above analysts' consensus estimates.

Robert A. Bradway, chairman and chief executive officer, said 'Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales.'